Tag - IMRX

Feature

Immuneering outpacing cancer with a novel approach to improving overall survival

Immuneering (NASDAQ: IMRX) is challenging conventional approaches of sustained inhibition in oncology by pioneering a novel class of therapies designed to outsmart cancer’s ability to adapt. With a proprietary platform...

October 28, 2025

Feature

Immuneering developing medicines for cancer patients with RAS mutations

Immuneering (NASDAQ:IMRX) is integrating translational medicine with bioinformatics to discover and develop novel product candidates for a broad population of cancer patients with RAS mutations, an approach the company...

August 15, 2023

Tag - IMRX

Immuneering outpacing cancer with a novel approach to improving overall survival

Immuneering developing medicines for cancer patients with RAS mutations

Subscribe